10 research outputs found
CHANGES OF LUMBOPELVIC RWTHM DURING TRUNK EXTENSION IN ADOLESCENT SOCCER PLAYERS
No full textHip-spine coordination (or lumbopelvic rhythm) can be used to assess the lower-limb and spine functions. We measured low-back pain (LBP) in adolescent soccer players before and after a 6-month period and divided them into four groups: no LBP both before and after the period, LBP before but not after 0,LB P after but not before (NP), and LBP both before and after. We used 3D motion analysis during trunk extension to measure the lumba spine and hip ranges of motion QOMs). During the 6-month follow-up, lumbar spine ROM decreased in the NP group. This group extended their lumbar spine excessively compared with the hip before the period, which could cause LBP, but decreased the extension after the period. Lumbar extension relative to hip extension decreased in the PN group, which could decrease the excessive load on the lumbar spine and eliminate LBP
COMPARISON OF LUMBOPELVIC RHYTHM AMONG ADOLESCENT SOCCER PLAYERS WITH AND WITHOUT LOW BACK PAIN
No full textDifference in kick motion of adolescent soccer players in presence and absence of low back pain
No full text
HAMSTRINGS TRAINING EFFECT ON HIP AND KNEE JOINT FUNCTION, MORPHOLOGY OF HAMSTRING MUSCLES, AND INJURY PREVENTION
No full textIs Increased Kicking Leg Iliopsoas Muscle Tightness a Predictive Factor for Developing Spondylolysis in Adolescent Male Soccer Players?
No full textJ1620202 Gait Analysis of Knee Osteoarthritis Patients by Using Approximate Plane of Elevation Angle : Confirmation of a Planar Law and Analysis of Angular Difference of the Approximate Plane
No full textHeterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
No full textBackground: Single-agent chemotherapy with or without bevacizumab (Bev) is a standard therapy for platinum-resistant ovarian cancer (PR-OC). However, there is a lack of literature on chemotherapy agent selection in heterogenous PR-OC. Therefore, we aimed to clarify the heterogeneous treatment effects of each chemotherapy agent. Methods: Patients who underwent single-drug chemotherapy agents or Bev combination therapy for PR-OC between January 2009 and June 2022 were included in this study. We assessed the impact of each chemotherapy agent on the time to treatment failure (TTF) according to histological type, platinum-free interval (PFI), and Bev usage. Results: A total of 158 patients received 343 different chemotherapy regimens. In patients with clear cell carcinoma/mucinous carcinoma (CC/MC), gemcitabine (GEM) had the strongest effect with a median TTF of 5.3 months, whilst nedaplatin (NDP) had the lowest effect with a median TTF of 1.4 months. In contrast, in the non-CC/MC group, irinotecan (CPT-11) and NDP had a better TTF than GEM and pegylated liposomal doxorubicin (PLD). There were notable differences in the treatment efficacy of NDP according to PFI. Specifically, NDP prolonged the TTF in patients with a PFI ≥ 3 months. Compared with GEM alone, GEM + Bev tended to prolong the TTF more effectively; however, an additive effect was not observed with PLD + Bev. Conclusions: This study demonstrated that the effect of chemotherapy agents differed according to the tumor and background characteristics of the patient. Our findings will improve selection of effective therapies for patients with PR-OC by considering their background characteristics. © 2023, The Author(s).Open access articleThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]
Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-κB pathway
No full text[No abstract available]Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016-S0305-7372(03)00081-1; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182-blood-2001-12-0372; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146-annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146-annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126-science.2843985; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016-S0952-7915(00)00107-2; Bazarbachi A, 1999, BLOOD, V93, P278; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016-S0168-1702(01)00286-6; Bazarbachi A, 2004, CANCER RES, V64, P2039, DOI 10.1158-0008-5472.CAN-03-2390; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; BERAUD C, 1996, J ACQ IMMUN DEF SYND, V13, P76; Bex F, 1998, MOL CELL BIOL, V18, P2392; Bex F, 1997, J VIROL, V71, P3484; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084-jem.179.3.901; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006-viro.1997.8509; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128-JVI.74.5.2351-2364.2000; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cascio P, 2002, EMBO J, V21, P2636, DOI 10.1093-emboj-21.11.2636; Chen GQ, 1996, BLOOD, V88, P1052; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016-S0092-8674(00)81064-8; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128-JVI.78.21.11823-11832.2004; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074-jbc.273.26.15891; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016-j.tcb.2004.01.004; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128-JVI.77.9.5286-5294.2003; El-Sabban ME, 2002, BLOOD, V99, P3383, DOI 10.1182-blood.V99.9.3383; El-Sabban ME, 2000, BLOOD, V96, P2849; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074-jbc.M210631200; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038-sj.onc.1206468; GESSAIN A, 1985, LANCET, V2, P407; Gessain A, 1996, ADV VIRUS RES, V47, P377, DOI 10.1016-S0065-3527(08)60740-X; Good LF, 1996, J VIROL, V70, P2730; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073-pnas.86.9.3351; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074-jbc.273.39.25185; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128-JVI.75.22.11106-11115.2001; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016-0092-8674(92)90083-O; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038-sj.thj.6200374; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146-annurev.biochem.67.1.425; HINUMA Y, 1982, GAN TO KAGAKU RYOHO, V8, P1313; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073-pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016-S0014-5793(02)03590-1; Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002-(SICI)1097-0215(19990812)82:4599::AID-IJC213.0.CO;2-R; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016-0092-8674(92)90082-N; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074-jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126-science.2309119; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016-0092-8674(95)90021-7; Kawakami A, 1999, BLOOD, V94, P3847; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084-jem.193.12.1361; LANOIX J, 1994, ONCOGENE, V9, P841; Lau A, 1998, BLOOD, V91, P2467; LEBAIL O, 1993, EMBO J, V12, P5043; Lomas M, 2002, J GEN VIROL, V83, P641; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016-S1097-2765(00)80259-2; Mahieux R, 2000, AIDS RES HUM RETROV, V16, P1677, DOI 10.1089-08892220050193137; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101-gad.7.4.705; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006-viro.1999.9685; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182-blood-2003-11-3967; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182-blood-2002-01-0151; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023-A:1011158021749; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038-sj.leu.2402777; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073-pnas.95.7.3537; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182-blood-2002-09-2986; Nasr R, 2005, ONCOGENE, V24, P419, DOI 10.1038-sj.onc.1208212; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126-science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038-sj.onc.1203239; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016-S0092-8674(94)90482-0; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006-viro.1994.1586; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089-08892220050193128; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182-blood.V98.4.1200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074-jbc.M201393200; Robek MD, 1999, J VIROL, V73, P4856; Rothwarf DM, 1998, NATURE, V395, P297; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038-381328a0; RYSECK RP, 1992, MOL CELL BIOL, V12, P674; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038-sj.leu.2403400; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038-sj.onc.1203220; SUN SC, 1994, MOL CELL BIOL, V14, P7377; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023-A:1023733231406; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006-viro.1999.9760; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1994, ONCOGENE, V9, P3099; Tamiya S, 1998, BLOOD, V91, P3935; Tan C, 2002, CANCER RES, V62, P1083; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073-pnas.87.3.1071; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093-emboj-19.1.94; Tojima Y, 2000, NATURE, V404, P778; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074-jbc.273.33.21132; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101-gad.9.22.2723; WALDMANN TA, 1993, BLOOD, V82, P1701; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093-emboj-16.6.1413; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038-sj.onc.1203894; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093-emboj-20.23.6805; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016-S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016-S0092-8674(00)81447-6; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146-annurev.immunol.19.1.475; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016-0092-8674(90)90806-P; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038-sj.onc.120485223222
